Efficacy and Safety of Seltorexant in Insomnia Disorder

Does seltorexant, a selective orexin-2 receptor antagonist, provide clinical benefit in insomnia disorder?In a randomized clinical trial including 364 adult participants with insomnia disorder, seltorexant showed a statistically significant dose-response relationship in latency to persistent sleep and wake after sleep onset over the first 6 hours on night 1 in the 10-mg and 20-mg groups vs placebo and in the 20-mg group vs zolpidem.Seltorexant, 10 mg and 20 mg, demonstrated efficacy in the initiation of sleep in participants with insomnia without psychiatric comorbidity.

Corresponding Author: Johnson smesens@its.jnj.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.